• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    97.full.pdf
    Size:
    907.6Kb
    Format:
    PDF
    Description:
    Full text, Open Access article
    Download
    Authors
    Trainer, Peter J
    Newell-Price, J
    Ayuk, J
    Aylwin, S
    Rees, D
    Drake, W
    Chanson, P
    Brue, T
    Webb, S
    Montañana, C
    Aller, J
    McCormack, A
    Torpy, D
    Tachas, G
    Atley, L
    Ryder, W David J
    Bidlingmaier, M
    Show allShow less
    Affiliation
    Department of Endocrinology, The Christie NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester
    Issue Date
    2018-05-22
    
    Metadata
    Show full item record
    Abstract
    Abstract OBJECTIVE: ATL1103 is a second-generation antisense oligomer targeting the human GH receptor. This phase 2 randomised, open-label, parallel-group study assessed the potential of ATL1103 as a treatment for acromegaly. DESIGN: 26 patients with active acromegaly (IGF-I >130% upper limit of normal) were randomised to subcutaneous ATL1103 200 mg either once- or twice-weekly for 13 weeks, and monitored for a further 8-week washout period. METHODS: The primary efficacy measures were change in IGF-I at week 14, compared to baseline and between cohorts. For secondary endpoints (IGFBP3, ALS, GH, GHBP), comparison was between baseline and week 14. Safety was assessed by reported adverse events. RESULTS AND CONCLUSIONS: Baseline median IGF-I was 447 and 649 ng/mL in the once- and twice-weekly groups, respectivey. Compared to baseline, at week 14 twice-weekly ATL1103 resulted in a median fall in IGF-I of 27.8% (p=0.0002). Between cohort comparison at week 14 demonstrated the median fall in IGF-I to be 25.8% (p=0.0012) greater with twice-weekly dosing. In the twice-weekly cohort, IGF-I was still declining at week 14, and at week 21 remained lower than at baseline by a median of 18.7% (p=0.0005). Compared to baseline, by week 14 IGFBP3 and ALS had declined by a median of 8.9% (p=0.027) and 16.7% (p=0.017) with twice-weekly ATL1103; GH had increased by a median of 46% at week 14 (p=0.001). IGFBP3, ALS and GH did not change with weekly ATL1103. GHBP fell by a median of 23.6% and 48.8% in the once- and twice-weekly cohorts (p=0.027 and p=0.005), respectively. ATL1103 was well tolerated, although 84.6% of patients experienced mild to moderate injection-site reactions (ISR). This study provides proof-of-concept that ATL1103 is able to significantly lower IGF-I in patients with acromegaly.
    Citation
    A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. 2018, Eur J Endocrinol
    Journal
    European Journal of Endocrinology
    URI
    http://hdl.handle.net/10541/621125
    DOI
    10.1530/EJE-18-0138
    PubMed ID
    29789410
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1530/EJE-18-0138
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1, -2, and -3.
    • Authors: Arosio M, Garrone S, Bruzzi P, Faglia G, Minuto F, Barreca A
    • Issue date: 2001 Mar
    • Successful use of weekly pegvisomant administration in patients with acromegaly.
    • Authors: Higham CE, Thomas JD, Bidlingmaier M, Drake WM, Trainer PJ
    • Issue date: 2009 Jul
    • Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly.
    • Authors: Hernandez I, Soderlund D, Espinosa-de-los-Monteros AL, Ochoa R, Zarate A, Mercado M
    • Issue date: 1999 Apr
    • Octreotide as primary therapy for acromegaly.
    • Authors: Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL
    • Issue date: 1998 Sep
    • Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
    • Authors: Marzullo P, Di Somma C, Pratt KL, Khosravi J, Diamandis A, Lombardi G, Colao A, Rosenfeld RG
    • Issue date: 2001 Jul
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.